VIDEO: Faricimab demonstrates positive real-world results at 1 year in neovascular AMD

ByArshad Khanani, MD, MA, FASRS

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, presents 1-year real-world findings for faricimab as a treatment for neovascular age-related macular degeneration.

According to Khanani, the results of the TRUCKEE study showed “rapid improvement in all anatomic parameters,” including central subfield thickness, presence of fluid and pigment epithelial detachments in both treatment-experienced and treatment-naive patients who received faricimab.

In addition, a subanalysis found that “inhibition of VEGF-A and Ang-2 with faricimab has benefits over treatments that just block VEGF only,” he said.

Published by:

Sources/Disclosures

Collapse

Source:

Khanani AM. Insights from clinical practice – Review of first year experience with faricimab in the real world. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).

Disclosures: Khanani reports consulting for and receiving research funding from Genentech.

Angiogenesis, Exudation and Degeneration Meeting

Read more

VIDEO: Faricimab demonstrates positive real-world results at 1 year in neovascular AMD

Related Content